A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis

Angiology

Volumn 57, Issue 1, 2006, Pages 53-64

  Cirujeda, J Lasierra ^a,c   Granado, P Coronel ^b  

^a HOSPITAL SAN PEDRO   (Spain)

^b Tedec Meiji Farma   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; SULODEXIDE; UROKINASE; UROKINASE VEDIM; ANTICOAGULANT AGENT; GLYCOSAMINOGLYCAN;

ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; FEMALE; HEALTH CARE; HUMAN; LEG; MAJOR CLINICAL STUDY; MALE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMORRHAGE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; AGED; BLOOD FLOW VELOCITY; DRUG EFFECT; ECHOGRAPHY; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; PILOT STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VEIN THROMBOSIS;

ACENOCOUMAROL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD FLOW VELOCITY; FEMALE; FOLLOW-UP STUDIES; GLYCOSAMINOGLYCANS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, COLOR; VENOUS THROMBOSIS;

EID: 33645277162     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970605700108     Document Type: Article

References (62)

1. Hull R, Delmore T, Carter C, et al: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 306:189-194, 1982.
2. Hull R, Hirsh J, Jay R, et al: Different intensities of oral anticoagulation therapy in the treatment of proximal vein thrombosis. N Engl J Med 307:1676-1681, 1982.
3. Anonymous: Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 340:873-876, 1992.
4. Brandjes D, Heijboer H, Buller R, et al: Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 327:1485-1489, 1992.
5. Nielsen HK, Husted SE, Krusell LR, et al: Anticoagulant therapy in deep venous thrombosis. A randomised controlled study. Thromb Res 72:215-226, 1994.
6. Ojiro M, Takenoshita M, Yamazumi K, et al: Clinical effects of a relatively small doses of urokinase. In: Fibrinolysis: Current Prospects, ed. by Gaffney PJ, Castellino FJ, Prow EF, et al. London, Paris: John Libbey, 1988, pp 213-215.
7. Lasierra J, Cuevas B, San Martin E, et al: Tratamiento de la trombosis venosa profunda con heparina y urocinasa. Cir Esp 65:404-408, 1999.
8. Anonymous: Multicenter study of 2 urokinase protocols in severe pulmonary embolism. Research Group on Urokinase and Pulmonary Embolism. Arch Mal Coeur Vaiss 77:773-781, 1984.
9. Gulba DC, Ficher C, Reil GH, et al: Potentiation of thrombolytic efficacy of single-chain urokinase (prourokinase) by heparin. Thromb Haematol 60:350-351, 1988.
10. Cercek B, Lew A, Hanoch H, et al: Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 74:583-587, 1986.
11. Schneider J: Interactions of saruplase with acetylsalicylic acid, heparin, glyceryl trinitrate, tranexamic acid and aprotinin in rabbit pulmonary thrombosis model. Arzneimittelforschung 40:1180-1184, 1990.
12. Schneider J: Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis. Thromb Res 64:677-689, 1991;
13. Andifuoli G, Mastacchi R, Barbanti M: Antithrombotic activity of glicosaminoglycan (Sulodexide) in rats. Thromb Res 34:81-85, 1984.
14. Barbanti M, Guizzardi S, Calanni F, et al: Antithrombotic and thrombolytic activity of sulodexide in rats. Int J Clin Res 22:179-184, 1992.
15. Ramos R, Blanco J, Hernández P, et al: Estudio prospectivo de profilaxis ambulatoria con sulodexida después de una artroplastia total de cadera o rodilla. Rev Esp Cir Osteoart 35:419-423, 2000.
16. Fiore G, Baraldi A, Gambarotta GC, et al: Inhibition of plasminogen activator (PAI-1) by sulodexide in postthrombophlebitic patients. J Drug Dev 3:173-178, 1991.
17. Pinto A, Corrao S, Galati D, et al: Sulodexide versus calcium heparin in the medium-term treatment of deep vein thrombosis of the lower limbs. Angiology 48:805-811, 1997.
18. Parnetti L, Mari D, Abate G, et al: Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results. Thromb Res 87:225-223, 1997.
19. Solini A, Vergnant L, Ricci F, et al: Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care 20:819-823, 1997.
20. Sorrenti G, Grimaldi M, Canova N, et al: Glycosaminoglycans as a possible tool for micro-and macroalbuminuria in diabetic patients. A pilot study. J Int Med Res 25:81-86, 1997.
21. Szelachowska M, Poplawska A, Toploska J, et al: A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients. Curr Med Res Opin 13:639-643, 1997.
22. Condorelli M, Chiarlello M, Dagianti A, et al: IPO-V2: A prospective multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial Infarction, J Am Coll Cardiol 23:27-34, 1994.
23. Certello A, Quatraro A, Marchi E, et al: Impaired fibrinolytic response to increased thrombin activation in type I diabetes mellitus: Effects of the glycosaminoglycam sulodexide. Diabetes Metab 19:225-229, 1993.
24. Saviano M, Maleti O, Liguorl L: Double-blind, double-dummy, randomized, multi-center clinical assessment of the efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency. Curr Med Res Opin 13:93-108, 1993.
25. Mauro M, Palmieri GC, Palazzini E, et al: Pharmacodynamic effects of single and repeated doses of oral sulodexide in healthy volunteers. A placebo-controlled study with an enteric-coated formulation Curr Med Res Opin 13:87-95, 1993.
26. Catania G, Salanitri T: Pharmacological treatment of intermittent claudication: Double blind controlled study of sulodexide vs placebo. Riv Eur Sci Med Farmacol 14:149-157, 1992.
27. Lunetta M, Salanitri T: Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease. J Int Med Res 20:45-53, 1992.
28. Crepaldi G, Rossi A, Coscetti G, et al: Sulodexide oral administration influences blood viscosity and fibrinolysls. Drugs Exp Clin Res 18:189-195, 1992.
29. Harenberg J: Review of pharmacodynamic, pharmacokinetic and therapeutic properties of sulodexide. Med Res Rev 1:1-20, 1998.
30. Milani MR, Busutti J, Breccia A, et al: Pharmacokinetics of sulodexide evaluated from I-131-labelled fast moving heparin after single intravenous and oral administration of different doses in man. Br J Clin Res 3:161-178, 1992.
31. Silvestro L, Llanzarotti E, Marchi E, et al: Human pharmacokinetic of glicosaminoglicans using deuterium labelled and unlabeled substances: Evidence for oral administration. Semin Thromb Haemost 20:281-292, 1994.
32. Gabriel F, Labiós M, Brasó JV: Trombosis venosa profunda: Presente y futuro. Med Clin 114:30-42, 2000.
33. Casado MA: Análisis parciales de evaluación económica de medicamentos: Descripción de costes, estudios de coste de la enfermedad, análisis coste-consecuencia, análisis de costes. Análisis de minimización de costes. In: Farmacoeconomía e investigación de resultados en la salud: Principios y práctica, ed. 2, ed. by Domínguez-Gil A, Soto J. Madrid: Real Academia Nacional de Farmacia, 2002, pp 173-208.
34. Drummond MF, O'Brien B, Stoddart GL, et al: Basic types of economic evaluation. Critical assessment of economic evaluation. In: Methods for the Economic Evaluation of Health Care Programmes, ed. 2, ed. by Drummond MF, O'Brien B, Stoddart GL, et al. Oxford: Oxford University Press, 1997, pp 6-51.
35. Soto J, Fernández-Cano P: Evaluación económica del uso de dalteparina sódica "versus" heparina no fraccionada en el tratamiento de la trombosis venosa profunda. Farm Hosp 21:111-116, 1996.
36. Caro JJ, Getsios D, Caro I, et al: Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. Pharmacoeconomics 20:593-602, 2002.
37. Sarasin FP, Bounameaux H: Out-of-hospital antithrombotic prophylaxis after total hip replacement: Low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis. Thromb Haemost 87:586-592, 2002.
38. Brosa M, Rubio-Terres C, Nadipelli V, et al: Análisis coste-efectividad de enoxaparina en la profilaxis de la enfermedad tromboembólica venosa en pacientes sometidos a cirugía mayor ortopédica. Farm Hosp 27:210-218, 2003.
39. Gordois A, Posnett J, Borris L, et al: The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major othopaedic surgery. J Thromb Haemost 1:2167-2174, 2003.
40. Sullivan SD, Kahn SR, Davidson BL, et al: Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics 21:477-496, 2003.
41. Committee for Propietary Medicinal Products (CPMP). Note for Guidance on Clinical Investigation of Medicinal Products for the Treatment of Venous Thromboembolic Disease (CPMP/EWP/563/98). London, December 1999.
42. Catálogo de Especialidades Farmacéuticas. Consejo General de Colegios Oficiales de Farmacéuticos, 2003.
43. Gisbert R, Brosa M: Base de Datos de Costes Sanitarios versión 1.6.Soikos, Barcelona, 2004.
44. Holm HA, Ly B, Handeland GF, et al: Risk factors for haemorrhage in outpatients taking warfarin. Ann Intern Med 120:897-902, 1994.
45. Bratt G, Tornebohm E, Granqvis S, et al: A comparison between low-molecular-weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Throm Haemost 54:813-817, 1985.
46. Hull RD, Carter CJ, Jay RM, et al: The diagnosis of acute recurrent deep-vein thrombosis: A diagnosis challenge. Circulation 67:901-906, 1983.
47. Huisman MV, Büller HR, ten Cate JW: Utility of impedance plethysmography in the diagnosis of recurrent deep-vein thrombosis. Arch Intern Med 148:681-683, 1988.
48. Douketis JD, Kearon C, Bates SH, et al: Risk of fatal pulmonary embolism in patients treated for venous thromboembolism. JAMA 279:458-462, 1998.
49. Gonzalez-Fajardo JA, Arreba E, Castrodez J, et al: Venographic comparison of subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 30:283-292, 1999.
50. Green D, Hirsh J, Heit J, et al: Low-molecular-weight heparin: A critical analysis of clinical trials. Pharmacol Rev 46:89-109, 1994.
51. Levine MN, Hirs J, Gent M, et al: Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemostasis 74:606-611, 1995.
52. Buchanan MR, Liao P, Smith LJ, et al: Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: Importance of heparin cofactor II. Thromb Res 74:463-475, 1994.
53. Di Stefano F, Vinci M: Terapia antitrombotic delle flebopatie con sulodexida. Studio controllato di efficacia e tollerabilitá. Med Pharmacol Scien 11:507-515, 1989.
54. Mauro M, Ferraro G, Palmieri G: Profibrinolytic and antithrombotic effects of sulodexide oral administration. A double-blind, crossover, placebo-controlled study. Ther Res 51:342-350, 1992.
55. Degiglio V, Guida C: Prevention of vascular complications from immobility using sulodexide. Med Praxis 11:1-7, 1990.
56. Errichi BM, Cesarone MR, Belcaro G, et al: Prevention of recurrent deep venous thrombosis with sulodexide: The San Val Registry. Angiology 55:243-249, 2004.
57. Hylek EM, Singer DE: Risk factor for intracranial hemorrhage in outpatients taking warfarin. Ann Int Med 120:897-902, 1994.
58. Landefeld CS, Rosenblatt MW, Goldman L: Bleeding in outpatients treated with warfarin: Relation to the prothrombin time and important remediable lesions. Am J Med 87:153-159, 1989.
59. Altman R, Rouvier J, Gurfinkel E, et al: Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 101:427-431, 1991.
60. Dass K, Cohen AT, Edmondson RA, et al: Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomized trial. World J Surg 20:521-527, 1996.
61. Pini M, Aiello S, Manotti C, et al: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 72:191-197, 1994.
62. Kearon C, Gent M, Hirsh J, et al: A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901-907, 1999.